Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 13/20 | 0.76 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.76 |
| ▸ | CDK2 | P24941 | 12/20 | 0.72 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.72 |
| ▸ | CCNE2 | O96020 | 8/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.64 |
| ▸ | CDK7 | P50613 | 4/20 | 0.64 |
| ▸ | CDK9 | P50750 | 4/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.64 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.64 |
| ▸ | CCNH | P51946 | 2/20 | 0.64 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.64 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.64 |
| ▸ | PDE5A | O76074 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016705 | 0.91 | CDK2 (0.69) | CDK1CDK5CDK2CCNE1CCNE2 | |
| SCHEMBL2364042 | 0.89 | CDK1 (0.87) | CDK1CDK5CDK2CCNE1CCNE2 | |
| SCHEMBL4277404 | 0.86 | CDK1 (1.00) | CDK1CDK5CDK2CCNE1CCNE2 | |
| SCHEMBL7098593 | 0.83 | KDM4E (0.70) | CDK1CDK5CDK2CCNE1CCNE2 | |
| SCHEMBL7006709 | 0.82 | CDK1 (0.61) | CDK1CDK5CDK2CCNE1CCNE2 | |
| SCHEMBL17450143 | 0.82 | CDK1 (0.66) | CDK1CDK5CDK2CCNE1CCNE2 | |
| SCHEMBL17450111 | 0.82 | CDK1 (0.66) | CDK1CDK5CDK2CCNE1CCNE2 | |
| SCHEMBL14071580 | 0.81 | CDK2 (0.85) | CDK1CDK5CDK2CCNE1CCNE2 | |
| SCHEMBL3680752 | 0.79 | CCNE1 (0.82) | CDK1CDK5CDK2CCNE1CCNE2 | |
| SCHEMBL6143053 | 0.79 | CDK2 (1.00) | CDK1CDK5CDK2CCNE1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076268-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF CYSTIC DISEASES | Genzyme Corporation (US) | 2009-07-08 | — | — | EP | claimed |
| EP-2010533-A2 | PROCESS FOR THE PREPARATION OF 2,6,9-TRISUBSTITUTED PURINES | Cyclacel Limited (GB) | 2009-01-07 | — | — | EP | claimed |
| WO-2008051502-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF CYSTIC DISEASES | GENZYME CORPORATION (US) | 2008-05-02 | — | — | WO | claimed |
| WO-2007110649-A2 | PROCESS FOR THE PREPARATION OF 2,6,9-TRISUBSTITUTED PURINES | CYCLACEL LIMITED (GB) | 2007-10-04 | — | — | WO | claimed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | claimed |
| WO-2017208019-A1 | DOSING REGIMEN FOR SAPACITABIN AND SELICICLIB | CYCLACEL LIMITED (GB) | 2017-12-07 | — | — | WO | disclosed |
| EP-3148532-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181737-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2015-12-03 | — | — | WO | disclosed |
| US-9173938-B2 | Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-8809350-B2 | Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases | CYCLACEL LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-20120309723-A1 | PURINE AND PYRIMIDINE CDK INHIBITORS AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | CYCLACEL LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-1799230-B1 | PURINE AND PYRIMIDINE CDK INHIBITORS AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | CYCLACEL LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| US-6620818-B1 | Administering indolin-2-one derivative as cyclin-dependent kinase inhibitor | SMITHKLINE BEECHAM CORPORATION | 2003-09-16 | — | — | US | disclosed |
| EP-1308447-A1 | Purine derivatives having antiproliferative properties and biological uses thereof | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2003-05-07 | — | — | EP | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| EP-1177016-A2 | COMPOSITION AND METHOD FOR PREVENTING/REDUCING THE SEVERITY OF SIDE EFFECTS OF CHEMOTHERAPY AND/OR RADIATION THERAPY | GLAXO GROUP LIMITED (GB) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000078299-A2 | COMPOSITION AND METHOD FOR PREVENTING/REDUCING THE SEVERITY OF SIDE EFFECTS OF CHEMOTHERAPY AND/OR RADIATION THERAPY | GLAXO GROUP LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| EP-0874847-A1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997020842-A1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | CDK1 3/4885CDK5 17/4885CDK2 2/4885 |
| US-20120309723-A1 | PURINE AND PYRIMIDINE CDK INHIBITORS AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | CDK9, CDK7, CDK2 | CDK1 14/4885CDK5 10/4885CDK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.